2016 ASH Annual Meeting

 

Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients 5/5 (1)

Chrissy H.Y. van Beurden-Tan, MSc
Health Economist and PhD Candidate
Department of Hematology
Erasmus MC Cancer Institute
Rotterdam, Netherlands
 

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis No ratings yet.

Abdallah Abou Zahr
Department of Leukemia
University of Texas MD Anderson
Cancer Center
Houston, Texas, United States
 

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study No ratings yet.

Hans Michael Kvasnicka, MD, PhD
Deputy Director and Chief Consultant
Senckenberg Institute of Pathology
Head of Hematopathology and Tumorpathology Section
University of Frankfurt
Frankfurt, Germany
 

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF) No ratings yet.

Denis-Claude Roy, MD
Professor of Medicine
Université de Montréal
Chief Executive Officer
CellCAN Regenerative Medicine and Cell
Therapy Network
Director of Research
Le CIUSSS de l’Est-de-l’Île-de-Montréal
Scientific Director
Centre of Excellence for Cellular Therapy
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
 

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy No ratings yet.

M. Lynn Savoie, MD, FRCPC
Clinical Associate Professor
Division of Hematology and Hematologic Malignancies
University of Calgary
Calgary, Alberta, Canada
 

Failure to Achieve Early Molecular Milestone within 3 Months is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure No ratings yet.

Dennis Kim, MD, PhD, FRCP(C)
Associate Professor of Medicine
Department of Medicine
University of Toronto
Clinical Investigator
Department of Medical Oncology and Hematology
Princess Margaret Cancer Centre
University Health Network & Mount Sinai Hospital
Toronto, Ontario, Canada
 

Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib (RUX) with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis (MF): Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders – Research Consortium (MPD-RC) No ratings yet.

Pierre Laneuville, MD, FRCP
Associate Professor of
Medicine and Oncology
McGill University Health Centre and Research Institute
Montreal, Quebec, Canada
 

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop No ratings yet.

Pierre Laneuville, MD, FRCP
Associate Professor of
Medicine and Oncology
McGill University Health Centre and Research Institute
Montreal, Quebec, Canada
 

Treatment-Free Remission Accomplished by Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial No ratings yet.

Dennis Kim, MD, PhD, FRCP(C)
Associate Professor of Medicine
Department of Medicine
University of Toronto
Clinical Investigator
Department of Medical Oncology and Hematology
Princess Margaret Cancer Centre
University Health Network & Mount Sinai Hospital
Toronto, Ontario, Canada
 

Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries No ratings yet.

Christopher Hillis, MD, FRCPC
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada